World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
145
Citations
95772
World Ranking
1367
National Ranking
795

Overview

Ross L. Levine is affiliated with the Memorial Sloan Kettering Cancer Center in the United States. Their research primarily focuses on medicine, with significant contributions in biochemistry, genetics, and molecular biology. The main subfields of study include hematology, molecular biology, genetics, cancer research, and oncology.

Their work extensively addresses topics related to acute myeloid leukemia research, myeloproliferative neoplasms diagnosis and treatment, cancer genomics and diagnostics, chronic myeloid leukemia treatments, protein degradation and inhibitors, epigenetics and DNA methylation, as well as single-cell and spatial transcriptomics.

Among recent publications are the following papers:

  • Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN, 2022, Blood
  • Cancer therapy shapes the fitness landscape of clonal hematopoiesis, 2020, Nature Genetics
  • Single-cell mutation analysis of clonal evolution in myeloid malignancies, 2020, Nature
  • The AIM2 inflammasome exacerbates atherosclerosis in clonal haematopoiesis, 2021, Nature
  • Quantifying the Expanding Landscape of Clinical Actionability for Patients with Cancer, 2023, Cancer Discovery

Frequent co-authors have included:

  • Eytan M. Stein (51 publications)
  • Martin S. Tallman (41 publications)
  • Robert L. Bowman (38 publications)
  • Wenbin Xiao (38 publications)
  • Michael F. Berger (37 publications)

Ross L. Levine's publications appear most often in the following venues:

  • Blood (83 publications)
  • bioRxiv (Cold Spring Harbor Laboratory) (26 publications)
  • Blood Advances (16 publications)
  • Cancer Research (16 publications)
  • Journal of Clinical Oncology (11 publications)

Best Publications

  • Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

    Hartmut Döhner;Elihu Estey;David Grimwade;Sergio Amadori

  • The landscape of somatic copy-number alteration across human cancers

    Rameen Beroukhim;Craig H. Mermel;Craig H. Mermel;Dale Porter;Guo Wei

  • Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.

    Ross L. Levine;Ross L. Levine;Martha Wadleigh;Jan Cools;Benjamin L. Ebert;Benjamin L. Ebert

  • Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation.

    Maria E. Figueroa;Omar Abdel-Wahab;Chao Lu;Patrick S. Ward

  • Prognostic relevance of integrated genetic profiling in acute myeloid leukemia

    Jay P. Patel;Mithat Gönen;Maria E. Figueroa;Hugo Fernandez

  • The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate

    Patrick S. Ward;Jay Patel;David R. Wise;Omar Abdel-Wahab

  • IDH mutation impairs histone demethylation and results in a block to cell differentiation

    Chao Lu;Patrick S. Ward;Patrick S. Ward;Gurpreet S. Kapoor;Dan Rohle;Dan Rohle

  • IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype

    Sevin Turcan;Daniel Rohle;Daniel Rohle;Anuj Goenka;Logan A. Walsh

  • Clinical effect of point mutations in myelodysplastic syndromes.

    Rafael Bejar;Kristen Stevenson;Omar Abdel-Wahab;Naomi Galili

  • MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.

    Yana Pikman;Benjamin H Lee;Thomas Mercher;Elizabeth McDowell

  • JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.

    Linda M. Scott;Wei Tong;Ross L. Levine;Mike A. Scott

  • Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia

    Eytan M. Stein;Eytan M. Stein;Courtney D. DiNardo;Daniel A. Pollyea;Amir T. Fathi

  • Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation.

    Kelly Moran-Crusio;Linsey Reavie;Alan Shih;Omar Abdel-Wahab

  • MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients

    Animesh D. Pardanani;Ross L. Levine;Terra Lasho;Yana Pikman

  • EZH2 Is Required for Germinal Center Formation and Somatic EZH2 Mutations Promote Lymphoid Transformation

    Wendy Béguelin;Relja Popovic;Matt Teater;Yanwen Jiang

  • Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis

    Lambert Busque;Jay P Patel;Maria E Figueroa;Aparna Vasanthakumar

  • Genetic Alterations Activating Kinase and Cytokine Receptor Signaling in High-Risk Acute Lymphoblastic Leukemia

    Kathryn G. Roberts;Ryan D. Morin;Jinghui Zhang;Martin Hirst

  • Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6.

    Qian Zhang;Kai Zhao;Qicong Shen;Yanmei Han

  • Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies

    Omar Abdel-Wahab;Ann Mullally;Cyrus Hedvat;Guillermo Garcia-Manero

  • The role of mutations in epigenetic regulators in myeloid malignancies

    Alan H. Shih;Omar Abdel-Wahab;Jay P. Patel;Ross L. Levine

Frequent Co-Authors

Omar Abdel-Wahab
Omar Abdel-Wahab Memorial Sloan Kettering Cancer Center
Martin S. Tallman
Martin S. Tallman Northwestern University
Ari Melnick
Ari Melnick Cornell University
Benjamin L. Ebert
Benjamin L. Ebert Harvard University
D. Gary Gilliland
D. Gary Gilliland Fred Hutchinson Cancer Research Center
Maria E. Arcila
Maria E. Arcila Memorial Sloan Kettering Cancer Center
Ahmet Zehir
Ahmet Zehir Natera (United States)
Scott A. Armstrong
Scott A. Armstrong Harvard University
Michael F. Berger
Michael F. Berger Memorial Sloan Kettering Cancer Center
Richard Koche
Richard Koche Memorial Sloan Kettering Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Medical careers offer diverse pathways beyond becoming a physician. Many students pursuing Medicine in the USA later seek specialized roles in healthcare administration, advanced clinical practice, or the pharmaceutical sector. Fortunately, there are flexible online degree options that can support your ambitions while managing costs and schedules.

If you are interested in healthcare management, a health care administration degree online is an accessible route. These programs focus on leadership skills, policy, and health systems, and can be completed while you work or study.

For those looking to take on upper-level roles, pursuing a master’s such as an MHA can provide a competitive advantage. Investigating mha degree cost is important, as affordability varies across institutions and scholarships.

Advanced clinical degrees like the DNP (Doctor of Nursing Practice) are also available online. Many choose cheapest dnp programs online to gain leadership, research, and practice skills without accumulating excessive debt.

Aspiring pharmacists can benefit from online pharmd programs that blend coursework with hands-on training. These options make healthcare careers more accessible for diverse learners.

Best Scientists Citing Ross L. Levine

Trending Scientists